The 15 analysts offering 12-month price forecasts for Travere Therapeutics Inc have a median target of 12.00, with a high estimate of 23.00 and a low estimate of 8.00. The median estimate represents a +38.89% increase from the last price of 8.64.
The current consensus among 16 polled investment analysts is to Buy stock in Travere Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.03
Reporting Date Feb 27
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.